Innate Pharma S.A. (IPHA) Income Statement
IPHA 2025 at a glance
Fiscal year ended December 31, 2025 · eurosIPHA revenue and net income
Where IPHA's revenue goes
2025Each bar shows an amount and its share of revenue. IPHA kept −1,764.5% of revenue as net income.
IPHA profit margins
IPHA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −77.9% | −63.6% | −47.5% | −17.0% |
| Gross profit | −77.9% | −22.6% | −32.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IPHA income statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €2.8M | €12.6M | €51.9M | €57.7M | €12.1M | €69.8M | €69.0M | €79.9M | €32.6M | €56.2M |
| Cost of revenue | €0 | €52.0M | €56.0M | €51.7M | €47.0M | €49.7M | €45.2M | €69.6M | €67.0M | €48.6M |
| Gross profit | €2.8M | €12.6M | €5.6M | €6.0M | −€22.3M | €20.1M | €23.8M | €10.3M | −€34.4M | €7.5M |
| Research & development | €43.6M | €52.0M | €56.0M | €51.7M | €47.0M | €49.7M | €1.6M | €69.6M | €67.0M | €48.6M |
| Sales, general & admin | €11.0M | €11.9M | €11.4M | €13.9M | €16.0M | €18.6M | €49.6M | €18.1M | €15.7M | €8.9M |
| Total operating expenses | €56.2M | €64.2M | €18.3M | €63.4M | €25.5M | €19.0M | €50.9M | €74.7M | €72.6M | €48.6M |
| Operating income | −€53.4M | −€51.6M | −€12.7M | −€57.4M | −€47.8M | €1.1M | −€27.1M | €5.1M | −€40.0M | €7.6M |
| Interest income | €1.3M | €2.4M | €3.2M | €4.8M | €6.3M | €4.9M | €1.6M | — | — | — |
| Interest expense | €440,000 | €566,000 | €640,000 | €288,000 | €312,000 | €341,000 | €229,445 | €102,000 | €113,000 | €124,000 |
| Income before taxes | −€49.2M | −€49.5M | −€7.6M | −€58.0M | −€45.5M | −€829,000 | −€20.8M | €2.7M | −€48.0M | €12.9M |
| Income taxes | −€6.0M | — | −€9.7M | €41.1M | €13.7M | €6.8M | €206,000 | −€333,000 | €368,000 | €301,000 |
| Net income | −€49.2M | −€49.5M | −€7.6M | −€58.1M | −€52.8M | −€64.0M | −€20.8M | €3.0M | −€48.4M | €12.6M |
| EBITDA | −€43.6M | −€46.9M | −€1.8M | −€12.3M | −€43.2M | €57.9M | €18.1M | €12.5M | −€35.6M | €10.8M |
| Gross margin | 100.0% | 100.0% | 10.8% | 10.4% | −184.1% | 28.8% | 34.5% | 12.9% | −105.3% | 13.4% |
| Operating margin | −1,916.9% | −408.6% | −24.4% | −99.6% | −394.9% | 1.5% | −39.2% | 6.4% | −122.5% | 13.5% |
| Net margin | −1,764.5% | −392.0% | −14.6% | −100.7% | −436.0% | −91.7% | −30.1% | 3.8% | −148.3% | 22.5% |
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Mar '25 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €3.2M | €0 | €0 | €4.9M | €276,000 | €12.3M | €16.6M | €21.4M | €10.7M | €35.3M | €20.1M | €8.3M |
| Cost of revenue | — | −€18.4M | −€18.4M | €20.5M | −€29.1M | €29.1M | €24.6M | €24.6M | €12.3M | €15.7M | €15.7M | €13.4M |
| Gross profit | — | €18.4M | €18.4M | −€15.7M | €29.4M | −€16.7M | −€3.1M | −€3.1M | −€1.6M | €19.6M | €4.4M | −€5.0M |
| Research & development | — | €22.9M | €22.9M | €20.5M | €22.9M | €29.1M | €24.6M | €24.6M | €12.3M | €28.4M | €15.7M | €25.2M |
| Sales, general & admin | — | €1.4M | €1.5M | €9.6M | €2.7M | €9.4M | €9.0M | €9.0M | €4.5M | €8.5M | €4.5M | €9.6M |
| Total operating expenses | €24.4M | €46.4M | €46.4M | €9.8M | €54.6M | €9.6M | €9.1M | €8.1M | €4.0M | €37.0M | €3.8M | €34.7M |
| Operating income | −€21.8M | −€28.0M | −€28.0M | −€25.4M | −€25.3M | −€26.3M | −€7.4M | −€12.3M | −€6.1M | −€5.3M | −€199,500 | −€28.8M |
| Interest expense | €172,287 | €2.9M | €2.9M | €250,110 | €34,000 | €600,000 | €3.0M | €3.0M | — | €324,000 | €94,000 | €94,000 |
| Income before taxes | −€22.5M | −€27.8M | −€27.8M | −€21.3M | −€24.7M | −€24.8M | −€4.4M | −€9.3M | −€4.6M | −€3.1M | €859,000 | −€68.1M |
| Income taxes | −€2.6M | −€3.0M | −€3.0M | — | — | — | −€9.8M | −€9.8M | — | −€4.9M | −€3.8M | −€3.8M |
| Net income | −€19.9M | −€27.6M | −€27.6M | −€21.3M | −€24.7M | −€24.8M | −€9.3M | −€9.3M | −€4.6M | €1.7M | €859,000 | −€64.4M |
| EBITDA | −€21.2M | −€30.7M | −€30.7M | −€24.7M | −€21.8M | −€25.2M | −€10.8M | −€10.4M | −€5.2M | €832,000 | €1.4M | −€10.1M |
| Gross margin | — | — | — | −322.2% | 10,634.8% | −135.5% | −18.9% | −14.6% | −14.6% | 55.5% | 21.8% | −60.7% |
| Operating margin | −692.1% | — | — | −523.2% | −9,152.9% | −213.1% | −44.8% | −57.2% | −57.2% | −14.9% | −1.0% | −346.7% |
| Net margin | −630.0% | — | — | −439.2% | −8,951.8% | −200.6% | −56.1% | −43.3% | −43.3% | 4.9% | 4.3% | −775.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in IPHA's financial statements (latest annual report filed April 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IPHA financial results
In fiscal year 2025 (ended December 31, 2025), Innate Pharma reported revenue of €2.8 million, down 77.9% from the year before. It had a net loss of €49.2 million, a net profit margin of −1,764.5%. Over five years revenue grew at an average rate of −47.5% a year. Figures are in euros, the currency of its financial statements.
See the IPHA stock overview for the latest quote and news, or the IPHA chart for price history and technical indicators.
IPHA income statement FAQ
What is Innate Pharma's annual revenue?
Innate Pharma reported total revenue of €2.8 million for fiscal year 2025, which ended on December 31, 2025. That was down 77.9% from €12.6 million the previous year.
Is Innate Pharma profitable?
No. Innate Pharma reported a net loss of €49.2 million in fiscal 2025, a net profit margin of −1,764.5%; its operating margin was −1,916.9%.
What is Innate Pharma's gross margin?
Innate Pharma's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Innate Pharma kept $100 after the direct cost of its products and services.
How much does Innate Pharma spend on research and development?
Innate Pharma spent €43.6 million on research and development in fiscal 2025, 1,565.1% of revenue.
How fast is Innate Pharma growing?
Revenue grew −47.5% a year on average over the last five fiscal years, from €69.8 million to €2.8 million.
When does Innate Pharma's fiscal year end?
Innate Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 1, 2026.